OKYO Pharma (OKYO) Competitors $3.27 +0.11 (+3.48%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.18 -0.09 (-2.60%) As of 08/8/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO vs. SIGA, UPXI, SVRA, ATYR, PRTC, FLGC, SNDL, CMPS, KOD, and ERASShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Siga Technologies (SIGA), Upexi (UPXI), Savara (SVRA), aTyr Pharma (ATYR), PureTech Health (PRTC), Flora Growth (FLGC), SNDL (SNDL), COMPASS Pathways (CMPS), Kodiak Sciences (KOD), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Its Competitors Siga Technologies Upexi Savara aTyr Pharma PureTech Health Flora Growth SNDL COMPASS Pathways Kodiak Sciences Erasca OKYO Pharma (NASDAQ:OKYO) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Which has better valuation & earnings, OKYO or SIGA? Siga Technologies has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$4.71MN/AN/ASiga Technologies$138.72M4.63$59.21M$1.137.93 Do analysts prefer OKYO or SIGA? OKYO Pharma currently has a consensus target price of $7.00, indicating a potential upside of 114.07%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than Siga Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Siga Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer OKYO or SIGA? In the previous week, Siga Technologies had 11 more articles in the media than OKYO Pharma. MarketBeat recorded 12 mentions for Siga Technologies and 1 mentions for OKYO Pharma. Siga Technologies' average media sentiment score of 0.53 beat OKYO Pharma's score of -0.51 indicating that Siga Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Siga Technologies 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, OKYO or SIGA? OKYO Pharma has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Do insiders and institutionals have more ownership in OKYO or SIGA? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is OKYO or SIGA more profitable? Siga Technologies has a net margin of 45.73% compared to OKYO Pharma's net margin of 0.00%. Siga Technologies' return on equity of 40.52% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Siga Technologies 45.73%40.52%35.62% SummarySiga Technologies beats OKYO Pharma on 9 of the 13 factors compared between the two stocks. Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.99M$2.99B$5.51B$9.72BDividend YieldN/A2.45%4.60%4.12%P/E RatioN/A17.2130.0124.75Price / SalesN/A312.02450.7297.72Price / CashN/A41.7736.7758.47Price / Book-20.447.318.185.59Net Income-$4.71M-$54.43M$3.26B$265.99M7 Day Performance5.48%0.01%6.13%5.07%1 Month Performance14.34%0.63%0.07%0.61%1 Year Performance228.64%8.41%36.31%22.83% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma2.7615 of 5 stars$3.27+3.5%$7.00+114.1%+227.0%$122.99MN/A0.007Upcoming EarningsAnalyst UpgradeGap UpSIGASiga Technologies2.0021 of 5 stars$6.58-1.0%N/A+3.1%$470.36M$138.72M9.8340News CoverageEarnings ReportAnalyst UpgradeOptions VolumeUPXIUpexi3.5904 of 5 stars$5.26+4.8%$15.50+194.7%+54.6%$470.04M$16.56M0.00130SVRASavara1.8162 of 5 stars$2.70+4.9%$5.60+107.6%-33.7%$466.15MN/A-5.6220Upcoming EarningsATYRaTyr Pharma2.0334 of 5 stars$5.22+3.9%$20.20+287.3%+191.2%$464.14M$230K-6.4453News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeAnalyst RevisionPRTCPureTech Health1.7998 of 5 stars$18.58-2.7%$45.00+142.2%-19.2%$446.41M$4.32M0.00100FLGCFlora Growth3.0991 of 5 stars$19.68-8.4%$156.00+692.9%-49.1%$444.07M$59.51M-22.36280News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionHigh Trading VolumeSNDLSNDL2.775 of 5 stars$1.67+1.5%$4.00+140.2%-18.4%$437.53M$671.81M-6.172,516CMPSCOMPASS Pathways2.8021 of 5 stars$4.49-2.5%$16.29+263.0%-37.8%$430.48MN/A-2.44120News CoverageAnalyst RevisionGap UpKODKodiak Sciences3.1672 of 5 stars$8.12+11.0%$9.00+10.9%+223.8%$428.15MN/A-2.2490Positive NewsUpcoming EarningsERASErasca2.4128 of 5 stars$1.51+7.5%$4.57+203.7%-41.7%$426.35MN/A-2.43120News CoverageUpcoming Earnings Related Companies and Tools Related Companies SIGA Alternatives UPXI Alternatives SVRA Alternatives ATYR Alternatives PRTC Alternatives FLGC Alternatives SNDL Alternatives CMPS Alternatives KOD Alternatives ERAS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKYO) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
